ATE255894T1 - Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen - Google Patents

Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Info

Publication number
ATE255894T1
ATE255894T1 AT99948905T AT99948905T ATE255894T1 AT E255894 T1 ATE255894 T1 AT E255894T1 AT 99948905 T AT99948905 T AT 99948905T AT 99948905 T AT99948905 T AT 99948905T AT E255894 T1 ATE255894 T1 AT E255894T1
Authority
AT
Austria
Prior art keywords
pain
treatment
anxiety
antagonists
mglur5 antagonists
Prior art date
Application number
AT99948905T
Other languages
English (en)
Inventor
Hans Allgeier
Nicholas David Cosford
Peter Josef Flor
Fabrizio Gasparini
Conrad Gentsch
Stephen D Hess
Edwin Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Mark Andrew Varney
Elebi Goenuel Veli
Katharine Walker
Original Assignee
Novartis Pharma Gmbh
Sibia Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE255894(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis Pharma Gmbh, Sibia Neurosciences Inc filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE255894T1 publication Critical patent/ATE255894T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
AT99948905T 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen ATE255894T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23
PCT/EP1999/007239 WO2000020001A1 (en) 1998-10-02 1999-09-30 Mglur5 antagonists for the treatment of pain and anxiety

Publications (1)

Publication Number Publication Date
ATE255894T1 true ATE255894T1 (de) 2003-12-15

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99948905T ATE255894T1 (de) 1998-10-02 1999-09-30 Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen

Country Status (21)

Country Link
EP (1) EP1117403B1 (de)
JP (1) JP2002526408A (de)
KR (1) KR20010088832A (de)
CN (1) CN1187048C (de)
AT (1) ATE255894T1 (de)
AU (1) AU765644B2 (de)
BR (1) BR9914215A (de)
CA (1) CA2345137A1 (de)
DE (1) DE69913548T2 (de)
DK (1) DK1117403T3 (de)
ES (1) ES2213389T3 (de)
HU (1) HUP0200553A3 (de)
ID (1) ID29095A (de)
IL (2) IL142047A0 (de)
NO (1) NO20011440L (de)
NZ (1) NZ510743A (de)
PL (1) PL202906B1 (de)
PT (1) PT1117403E (de)
RU (1) RU2232017C2 (de)
SK (1) SK4382001A3 (de)
WO (1) WO2000020001A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
CN1260226C (zh) 2000-12-22 2006-06-21 弗·哈夫曼-拉罗切有限公司 用作mGluR1拮抗剂的四氢－(苯并或噻吩并)－氮杂䓬－吡嗪和三嗪衍生物
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
HUE032743T2 (en) 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
AU2016273751B2 (en) 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3459939A1 (de) 2017-09-26 2019-03-27 Pragma Therapeutics Neuartige heterocyclische verbindungen als mglur7 modulatoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
SK4382001A3 (en) 2001-08-06
NZ510743A (en) 2003-10-31
AU6198499A (en) 2000-04-26
AU765644B2 (en) 2003-09-25
PL202906B1 (pl) 2009-08-31
HUP0200553A3 (en) 2002-11-28
IL142047A0 (en) 2002-03-10
DE69913548T2 (de) 2004-09-23
CN1187048C (zh) 2005-02-02
DE69913548D1 (de) 2004-01-22
NO20011440L (no) 2001-05-15
KR20010088832A (ko) 2001-09-28
NO20011440D0 (no) 2001-03-21
DK1117403T3 (da) 2004-04-13
PT1117403E (pt) 2004-04-30
WO2000020001A1 (en) 2000-04-13
RU2232017C2 (ru) 2004-07-10
JP2002526408A (ja) 2002-08-20
BR9914215A (pt) 2001-07-03
HUP0200553A2 (hu) 2002-07-29
PL346876A1 (en) 2002-03-11
CA2345137A1 (en) 2000-04-13
IL142047A (en) 2007-09-20
ID29095A (id) 2001-07-26
EP1117403B1 (de) 2003-12-10
ES2213389T3 (es) 2004-08-16
EP1117403A1 (de) 2001-07-25
CN1321087A (zh) 2001-11-07

Similar Documents

Publication Publication Date Title
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60141230D1 (de) Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
DE60233040D1 (de) Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
ATE267595T1 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1117403

Country of ref document: EP